You’re using a public version of DrugPatentWatch with 1 free search available | Register to unlock more free searches. CREATE FREE ACCOUNT

Serving leading biopharmaceutical companies globally:

Colorcon
McKinsey
Express Scripts
Baxter
Merck
Boehringer Ingelheim

Last Updated: February 22, 2024

Amylyx Company Profile


✉ Email this page to a colleague

« Back to Dashboard


Summary for Amylyx
International Patents:49
US Patents:5
Tradenames:1
Ingredients:1
NDAs:1

Drugs and US Patents for Amylyx

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Amylyx RELYVRIO sodium phenylbutyrate; taurursodiol FOR SUSPENSION;ORAL 216660-001 Sep 29, 2022 RX Yes Yes 11,071,742 ⤷  Try a Trial Y ⤷  Try a Trial
Amylyx RELYVRIO sodium phenylbutyrate; taurursodiol FOR SUSPENSION;ORAL 216660-001 Sep 29, 2022 RX Yes Yes 10,857,162 ⤷  Try a Trial ⤷  Try a Trial
Amylyx RELYVRIO sodium phenylbutyrate; taurursodiol FOR SUSPENSION;ORAL 216660-001 Sep 29, 2022 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial
Amylyx RELYVRIO sodium phenylbutyrate; taurursodiol FOR SUSPENSION;ORAL 216660-001 Sep 29, 2022 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial
Amylyx RELYVRIO sodium phenylbutyrate; taurursodiol FOR SUSPENSION;ORAL 216660-001 Sep 29, 2022 RX Yes Yes 10,251,896 ⤷  Try a Trial ⤷  Try a Trial
Amylyx RELYVRIO sodium phenylbutyrate; taurursodiol FOR SUSPENSION;ORAL 216660-001 Sep 29, 2022 RX Yes Yes 11,583,542 ⤷  Try a Trial Y ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for Amylyx Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1175904 2007C/048 Belgium ⤷  Try a Trial PRODUCT NAME: ALENDRONATE DE SODIUM/COLECALCIFEROL; AUTHORISATION NUMBER AND DATE: EU/1/05/310/001 20050826
2932970 18C1043 France ⤷  Try a Trial PRODUCT NAME: UNE COMBINAISON COMPRENANT DU DOLUTEGRAVIR OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI,EN PARTICULIER LE SEL DE SODIUM DU DOLUTEGRAVIR,ET DE LA RILPIVIRINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI,EN PARTICULIER LE CHLORHYDRATE DE RILPIVIRINE; REGISTRATION NO/DATE: EU/1/18/1282 20180518
0145340 99C0005 Belgium ⤷  Try a Trial PRODUCT NAME: FOSPHENYTOIN DISODIUM; NAT. REGISTRATION NO/DATE: NL 23 613 19980806; FIRST REGISTRATION: GB - PL 000 19/0157 19980204
2340828 LUC00195 Luxembourg ⤷  Try a Trial PRODUCT NAME: SACUBITRIL ET VALSARTAN, SOUS FORME DE COMPLEXE DE SEL DE SODIUM SACUBITRIL VALSARTAN, C'EST-A-DIRE (((S)-N-VALERYL-N-((2'-(1H-TETRAZOLE-5-YL)-BIPHENYL-4-YL)-METHYL)-VALINE) ((2R,4S)-5-BIPHENYL-4-YL-4-(3-CARBOXY-PROPIONYLAMINO)-2-METHYL-ESTER ETHYLIQUE D'ACIDE PENTANOIQUE))NA3 X H2O, DANS LEQUEL X EST 0 A 3; AUTHORISATION NUMBER AND DATE: EU/1/15/1058 20151123
2666774 CR 2020 00037 Denmark ⤷  Try a Trial PRODUCT NAME: RELEBACTAM, OPTIONALLY IN THE FORM OF THE MONOHYDRATE, IMIPENEM AND CILASTATIN, OPTIONALLY IN THE FORM OF THE SODIUM SALT; REG. NO/DATE: EU/1/19/1420 20200217
1758590 LUC00029 Luxembourg ⤷  Try a Trial PRODUCT NAME: SEL DE SODIUM D'ACIDE DEOXYCHOLIQUE; AUTHORISATION NUMBER AND DATE: IS/1/16/071/01 20170401
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
AstraZeneca
McKinsey
Express Scripts
Boehringer Ingelheim
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.